[go: up one dir, main page]

PE20061435A1 - Derivados de alfa-aminoacidos como ligandos del receptor alfa-2-delta - Google Patents

Derivados de alfa-aminoacidos como ligandos del receptor alfa-2-delta

Info

Publication number
PE20061435A1
PE20061435A1 PE2006000431A PE2006000431A PE20061435A1 PE 20061435 A1 PE20061435 A1 PE 20061435A1 PE 2006000431 A PE2006000431 A PE 2006000431A PE 2006000431 A PE2006000431 A PE 2006000431A PE 20061435 A1 PE20061435 A1 PE 20061435A1
Authority
PE
Peru
Prior art keywords
alpha
amino
ligands
alkyl
acid
Prior art date
Application number
PE2006000431A
Other languages
English (en)
Inventor
Shelley Rene Graham
Simon John Mantell
Jacob Bradley Schwarz
David James Rawson
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36677128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061435(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PE20061435A1 publication Critical patent/PE20061435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE ALFA-AMINOACIDOS a,a-DISUSTITUIDOS DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALO, R5, OR5 O SR5, DONDE R5 ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; R2 ES METILO OPCIONALMENTE SUSTITUIDO CON FLUOR; R3 ES H, ALQUILO(C1-C6), INDANILO, ENTRE OTROS; R4 ES H, ALQUIL(C1-C6)-C(O), ARIL-C(O) O UN RESTO -AMINOACIDO NATURAL UNIDO A TRAVES DE SU GRUPO CARBOXILO PARA FORMAR UNA AMIDA. SON COMPUESTOS PREFERIDOS: ACIDO (2S)-2-AMINO-4-ETIL-2-METILHEXANOICO, ACIDO (2S)-2-AMINO-3-CICLOPENTIL-2-METILPROPANOICO, ACIDO (2S)-2-AMINO-5-ETIL-2-METILHEPTANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR ALFA-2-DELTA ( 2 ) DEL CANAL DE CALCIO HUMANO SIENDO UTILES EN EL TRATAMIENTO DE DOLOR NEUROPATICO, EPILEPSIA, FIBROMIALGIA, HIPOCINESIA
PE2006000431A 2005-04-28 2006-04-25 Derivados de alfa-aminoacidos como ligandos del receptor alfa-2-delta PE20061435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67602505P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
PE20061435A1 true PE20061435A1 (es) 2007-02-03

Family

ID=36677128

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000431A PE20061435A1 (es) 2005-04-28 2006-04-25 Derivados de alfa-aminoacidos como ligandos del receptor alfa-2-delta

Country Status (26)

Country Link
US (1) US7612226B2 (es)
EP (1) EP1879567A1 (es)
JP (2) JP4173909B1 (es)
KR (1) KR100925900B1 (es)
CN (1) CN101166524B (es)
AP (1) AP2007004161A0 (es)
AR (1) AR054441A1 (es)
AU (1) AU2006238933B2 (es)
BR (1) BRPI0609879A2 (es)
CA (1) CA2606353C (es)
CR (1) CR9472A (es)
DO (1) DOP2006000095A (es)
EA (1) EA200701852A1 (es)
GT (1) GT200600178A (es)
IL (1) IL185790A0 (es)
MA (1) MA29408B1 (es)
MX (1) MX2007010978A (es)
NL (1) NL1031705C2 (es)
NO (1) NO20076000L (es)
PE (1) PE20061435A1 (es)
SV (1) SV2008002512A (es)
TN (1) TNSN07400A1 (es)
TW (1) TW200719889A (es)
UY (1) UY29498A1 (es)
WO (1) WO2006114707A1 (es)
ZA (1) ZA200707678B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
JP4173909B1 (ja) * 2005-04-28 2008-10-29 ファイザー・リミテッド アミノ酸誘導体
WO2007057767A2 (en) * 2005-11-17 2007-05-24 Pfizer Limited Amino acid derivatives
US8278355B2 (en) 2006-09-12 2012-10-02 Therexcell Pharma Inc. Isovaline for treatment of pain
CN101195583B (zh) * 2006-12-04 2012-07-04 四川抗菌素工业研究所有限公司 一种光学纯米那普仑及其盐的制备方法
BRPI0918526B1 (pt) * 2008-09-09 2022-02-15 F. Hoffmann-La Roche Ag Forma cristalina polimórfica anidra de acil sulfonamidas, seu processo de preparação, uso e composição farmacêutica que a compreende
JP2012176902A (ja) * 2011-02-25 2012-09-13 Tosoh F-Tech Inc 新規な光学活性含フッ素化合物、その製造方法及びそれを用いた光学活性３，３，３−トリフルオロアラニンの製造方法
AT514349B1 (de) * 2013-06-12 2018-05-15 Red Bull Gmbh Alpha-alkylierte Aminosäuren (AAAAs)

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB504209A (en) 1937-12-14 1939-04-21 Pirelli General Cable Works Improvements in or relating to electric cables
BR6239521D0 (pt) * 1961-08-09 1973-06-14 Merck & Co Inc Processo de preparacao de novos amino acidos
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3811256A1 (de) 1988-04-02 1989-10-19 Hoechst Ag (alpha)-trifluormethylaminosaeure-derivate, verfahren zur herstellung von (alpha)-trifluormethylaminosaeure-derivaten und ihre verwendung als arzneimittel
WO1991001724A1 (en) 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
JPH042899A (ja) 1990-04-16 1992-01-07 Arakawa Chem Ind Co Ltd 紙用サイズ剤および該サイズ剤を用いる紙サイジング方法
FR2661909B1 (fr) 1990-05-09 1997-08-14 Inst Nat Sante Rech Med Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.
JPH051002A (ja) 1991-02-15 1993-01-08 Nikko Kyodo Co Ltd α−アミノ酸の製造方法
CA2068038A1 (en) 1991-05-08 1992-11-09 Christopher Yee Enzymatic resolution of .alpha.-tertiary carboxylic acid esters
US5993775A (en) 1991-11-27 1999-11-30 Diatide, Inc. Radioactively labeled peptides comprising a single thiol moiety
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
WO1994008577A1 (en) 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5362747A (en) 1992-11-25 1994-11-08 Abbott Laboratories 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase
GB9325368D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
GB9325360D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE19533617A1 (de) 1995-09-11 1997-03-13 Degussa Neues Verfahren zur Herstellung von optisch aktiven alpha-Aminosäuren und alpha-Aminosäure-Derivaten
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
US5962523A (en) 1996-10-25 1999-10-05 Discovery Laboratories, Inc. Methods of using butyric acid derivatives to protect against hair loss
JPH10333511A (ja) 1997-05-30 1998-12-18 Ricoh Co Ltd 画像除去促進液、該画像除去促進液を用いた被記録材の再生方法及び再生装置
JP4205191B2 (ja) 1997-12-26 2009-01-07 ダイセル化学工業株式会社 α−アミノニトリル誘導体及びα−アミノ酸の製造方法
DE99907899T1 (de) 1998-03-11 2005-01-13 Kabushiki Kaisha Soken Hautnormalisierungsmittel
WO1999054280A1 (en) * 1998-04-17 1999-10-28 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
EP1140945B1 (en) 1998-12-18 2003-06-04 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2000037422A2 (en) 1998-12-22 2000-06-29 Neurosearch A/S Ion channel modulating agents
FR2788271B1 (fr) 1999-01-07 2001-02-09 Rhone Poulenc Agrochimie Nouveau procede de preparation d'aminoacides chiraux
EP1144360B1 (en) 1999-01-22 2005-04-27 PharmaCore, Inc, A method for the synthesis of compounds of formula 1 and derivatives thereof
AU2320300A (en) 1999-01-28 2000-08-18 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
WO2001009117A1 (en) 1999-07-29 2001-02-08 Allellix Neuroscience Inc. Tricyclic compounds as glycine transport inhibitors
FR2796943A1 (fr) 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
CA2384080C (en) 1999-09-07 2012-03-20 Kabushiki Kaisha Soken Skin conditioner
EP1219593A4 (en) 1999-09-07 2004-09-01 Mitsubishi Rayon Co PROCESS RELATING TO THE PRODUCTION OF OPTICALLY ACTIVE AMINOALCOOL
JP2001081013A (ja) 1999-09-10 2001-03-27 Soken Kk 毛髪健全化剤
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US6656958B2 (en) 2000-02-02 2003-12-02 Abbott Laboratories Substituted pyridine compounds useful for controlling chemical synaptic transmission
DE10121026A1 (de) 2000-05-05 2002-02-07 Basf Ag Verfahren zur Herstellung von Aldehyden
DE10121028A1 (de) 2000-05-05 2002-01-31 Basf Ag Verfahren zur Herstellung von Aldehyden
EP1300392B1 (en) 2000-05-18 2012-09-05 Mitsubishi Rayon Co., Ltd. Process for producing optically active alpha-amino acid and optically active alpha-amino acid amide
WO2003011799A1 (en) 2000-07-31 2003-02-13 Brandeis University Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
AUPR406901A0 (en) 2001-03-29 2001-04-26 La Trobe University Insecticide and method of controlling insects
JP4715058B2 (ja) 2001-08-02 2011-07-06 Ｊｓｒ株式会社 感放射性樹脂組成物
JP2003221328A (ja) 2002-01-29 2003-08-05 Soken Kk 皮膚健全化剤
EP1506162B1 (en) 2002-05-15 2008-11-26 Genzyme Corporation Synthesis of benzonitriles and benzimidates
JP2006504664A (ja) 2002-08-01 2006-02-09 ビーエーエスエフ アクチェンゲゼルシャフト 農薬フルオロアルケン誘導体
WO2004024709A2 (en) * 2002-09-13 2004-03-25 Prescient Neuropharma Inc. Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors
AU2003289242A1 (en) 2003-01-10 2004-08-10 Kaneka Corporation PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-METHYLCYSTEINE DERIVATIVE
JP2005060311A (ja) * 2003-08-13 2005-03-10 Mochida Pharmaceut Co Ltd Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
JPWO2005044780A1 (ja) 2003-11-10 2007-05-17 杏林製薬株式会社 アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
TW200642687A (en) * 2005-03-01 2006-12-16 Pfizer Ltd Combinations comprising α-2-δ ligands
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
EP1861359B1 (en) * 2005-03-17 2012-11-14 Pfizer Inc. N-(n-sulfonylaminomethyl)cyclopropanecarboxamide derivatives useful for the treatment of pain
JP4173909B1 (ja) * 2005-04-28 2008-10-29 ファイザー・リミテッド アミノ酸誘導体
MEP0408A (xx) * 2005-12-02 2010-02-10 Pfizer Ltd Derivati hinociklicnog hinazolina kao inhibitori pde7

Also Published As

Publication number Publication date
NO20076000L (no) 2008-01-28
CN101166524A (zh) 2008-04-23
AU2006238933B2 (en) 2011-12-01
UY29498A1 (es) 2006-11-30
HK1116417A1 (en) 2008-12-24
CA2606353C (en) 2011-11-22
JP4173909B1 (ja) 2008-10-29
US7612226B2 (en) 2009-11-03
US20060247291A1 (en) 2006-11-02
CA2606353A1 (en) 2006-11-02
AP2007004161A0 (en) 2007-10-31
WO2006114707A1 (en) 2006-11-02
ZA200707678B (en) 2009-08-26
EA200701852A1 (ru) 2008-04-28
CN101166524B (zh) 2010-12-22
BRPI0609879A2 (pt) 2010-05-11
KR20070116663A (ko) 2007-12-10
JP2008539221A (ja) 2008-11-13
GT200600178A (es) 2006-11-28
JP2009040767A (ja) 2009-02-26
AU2006238933A1 (en) 2006-11-02
TNSN07400A1 (fr) 2009-03-17
SV2008002512A (es) 2008-02-08
DOP2006000095A (es) 2006-10-15
CR9472A (es) 2007-12-04
TW200719889A (en) 2007-06-01
AR054441A1 (es) 2007-06-27
MA29408B1 (fr) 2008-04-01
EP1879567A1 (en) 2008-01-23
NL1031705A1 (nl) 2006-11-01
NL1031705C2 (nl) 2007-05-08
MX2007010978A (es) 2007-09-19
IL185790A0 (en) 2008-01-06
KR100925900B1 (ko) 2009-11-09

Similar Documents

Publication Publication Date Title
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
PE20190914A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
ES2523732T3 (es) Control de composiciones de copolímeros
ATE415387T1 (de) Verfahren zur herstellung von benzonitrilen und benzimidosäure-derivaten
CY1117449T1 (el) Φαινυλιουχα ν-ακυλο παραγωγα αμινων και αμινοξεων, μεθοδοι για την παραγωγη αυτων, μια φαρμακευτικη συνθεση και η χρηση αυτων
SE1651735A1 (en) Substances for treatment of fatty liver-related conditions
EA200970428A1 (ru) [f-18]-меченая l-глутаминовая кислота, [f-18]-меченый l-глутамин, их производные и их применение, а также способ их получения
PE20061435A1 (es) Derivados de alfa-aminoacidos como ligandos del receptor alfa-2-delta
EA201001766A1 (ru) Новые[f-18]-меченые производные l-глутаминовой кислоты и l-глутамина (i), их применение, а также способ их получения
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
ATE557096T1 (de) L-tryptophan produzierendes bakterium und verfahren zur produktion von l-tryptophan
EA200701810A1 (ru) Производное изоксазолина и новый способ его получения
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
ES2729198T3 (es) Preparación de derivados de pirrolidina
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
BR0206730A (pt) Processo para preparar uma composição de valproato de sódio não-higroscópica, composição farmacêutica não-higroscópia e seu uso
PE20060640A1 (es) Derivados del acido alcanoico arilcicloalquil-sustituidos y procedimientos para su preparacion
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
EA201070603A1 (ru) Лекарственное средство, активное в отношении невропатической боли
PE20100139A1 (es) Nuevas n-(2-amino-fenil)-acrilamidas
CY1111730T1 (el) Διαδικασια για την παρασκευη γκαμπαπεντινης
IL190399A (en) METHOD FOR PREPARING SQUARE ACID AND @ AMONIUM SALTS
RU2013108755A (ru) Терапевтическое средство или профилактическое средство для нейропатической боли
AR066371A1 (es) Formulaciones de aminoacidos n-halogenados que contienen acidos alifaticos

Legal Events

Date Code Title Description
FC Refusal